OncoMatch/Clinical Trials/NCT07082803
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Is NCT07082803 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including TLN-121 and TLN-254 for lymphoma.
Treatment: TLN-121 · TLN-254 · TLN-121 — The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
DLBCL, NOS, FL grade 3b, or transformed lymphoma from FL following at least 2 prior lines of therapy
Must have received: systemic therapy
FL grade 1-3a that requires treatment following at least 2 prior lines of therapy
Must have received: systemic treatment regimen
Peripheral T-cell lymphoma (PTCL) subtypes that have relapsed after, or not responded to at least 1 prior systemic treatment regimen
Must have received: systemic treatment regimen
High-Grade B-Cell Lymphoma that has relapsed after, or not responded to at least 2 prior systemic treatment regimens
Cannot have received: autologous stem cell transplantation
history of autologous stem cell transplantation within 60 days prior to the start of the study
Cannot have received: allogeneic stem cell transplantation
history of allogeneic stem cell transplantation within 90 days prior to the start of the study
Cannot have received: CAR T-cell or other T-cell targeting treatment
history of CAR T-cell or other T-cell targeting treatment ≤ 4 weeks prior to the start of the study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Medicine Cancer Center · Palo Alto, California
- The START Center for Cancer Care - Midwest · Grand Rapids, Michigan
- Washington University School of Medicine · St Louis, Missouri
- Memorial Sloan Kettering Cancer Center · New York, New York
- SCRI Oncology Partners · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify